Immunovant, Inc. (IMVT)
25.80
-0.23
(-0.88%)
USD |
NASDAQ |
Jan 12, 16:00
25.80
0.00 (0.00%)
After-Hours: 17:45
Immunovant Research and Development Expense (Quarterly): 114.25M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revvity, Inc. | 50.80M |
| Viridian Therapeutics, Inc. | 86.15M |
| Perspective Therapeutics, Inc. | 19.56M |
| Electromed, Inc. | 0.241M |
| InfuSystem Holdings, Inc. | -- |